About Alzinova
Alzinova AB is a Swedish pharmaceutical enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers.
Press Releases
-
2019-05-21
Uppdaterad tidsplan för klinisk studie, fas 1B
-
2019-05-20
Ledning och styrelse har utnyttjat optioner i Alzinova
-
2019-05-16
Kommuniké från Alzinova AB årsstämma den 16 maj 2019
-
2019-04-12
KALLELSE TILL ÅRSSTÄMMA i Alzinova AB (publ)
-
2019-03-28
Alzinova presenterar idag på Investor AW i Göteborg
-
2019-03-27
Alzinova presenterar idag på AD/PD kongressen i Lissabon